Shares of Mesoblast limited (NASDAQ:MESO) have been given an average rating of “Buy” by the eight ratings firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $14.13.
MESO has been the topic of several research analyst reports. Cantor Fitzgerald reiterated a “buy” rating and issued a $23.00 price objective on shares of Mesoblast in a report on Thursday, June 21st. HC Wainwright set a $17.00 target price on shares of Mesoblast and gave the stock a “buy” rating in a research note on Monday, July 2nd. Zacks Investment Research lowered shares of Mesoblast from a “hold” rating to a “sell” rating in a research note on Wednesday, July 4th. ValuEngine raised shares of Mesoblast from a “sell” rating to a “hold” rating in a research note on Thursday, July 5th. Finally, Maxim Group raised their target price on shares of Mesoblast from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Wednesday, July 18th.
An institutional investor recently bought a new position in Mesoblast stock. Jane Street Group LLC bought a new position in Mesoblast limited (NASDAQ:MESO) during the first quarter, according to its most recent Form 13F filing with the SEC. The firm bought 17,731 shares of the company’s stock, valued at approximately $102,000. 2.76% of the stock is owned by institutional investors.
Mesoblast (NASDAQ:MESO) last posted its quarterly earnings data on Wednesday, August 29th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.01. Mesoblast had a negative return on equity of 10.48% and a negative net margin of 203.51%. The company had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $2.51 million. As a group, equities analysts forecast that Mesoblast will post -0.97 EPS for the current fiscal year.
Mesoblast Company Profile
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.
Recommended Story: Marijuana Stocks Future Looks Bright
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.